ArticleBMC genomics2025
Performance comparison of four exome capture platforms on DNBSEQ-Series high throughput sequencer.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic characterization and niche adaptive analysis ofFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Whole exome sequencing (WES) technology has become a prevalent methodology in the field of human genetics research, providing an effective and affordable alternative to identify causative genetic mutations in genomic exon regions. This study focuses on the comparative assessment of four commercially available WES platforms on the DNBSEQ-Series sequencer, a platform that has not been extensively evaluated in the literature. The study provides a comprehensive comparison of data quality, capture specificity, coverage uniformity and variants detection accuracy across these platforms. The results indicate that these platforms exhibit comparable reproducibility and superior technical stability and detection accuracy on the DNBSEQ-T7 sequencer. Furthermore, the study establishes a robust workflow for probe hybridization capture that is compatible with the four commercial exome kits and the DNBSEQ-Series sequencer, offering uniform and outstanding performance, thus enhancing broader compatibility regardless of probe brand. This study contributes to filling a significant gap in the literature regarding the performance evaluation of WES platforms on the DNBSEQ-Series sequencer and provides valuable insights for researchers in human genetics research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.